Challenges in the diagnosis of the right patient for testosterone replacement therapy

被引:3
|
作者
Wang, Christina [1 ]
机构
[1] Univ Calif Los Angeles, Harbor Med Ctr, David Geffen Sch Med, Torrance, CA 90509 USA
关键词
androgen deficiency; diagnosis; hypogonadism; serum testosterone; testosterone deficiency syndrome; testosterone replacement therapy;
D O I
10.1016/j.eursup.2007.08.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Diagnosis of testosterone deficiency is important to identify patients who might benefit from testosterone replacement therapy. Unfortunately, the diagnosis of hypogonadism may be a challenge for many practicing physicians, including endocrinologists and urologists. Signs and symptoms, such as sexual dysfunction, change in body composition, lethargy, and mood changes, are nonspecific and the available questionnaires are generally not useful in clinical practice. The diagnosis of testosterone deficiency is ultimately based on measurement of serum testosterone levels. However, marked variations in the reference ranges of serum testosterone levels among laboratories pose a challenge for physicians when interpreting the results. In addition, initial laboratory assessments usually determine total testosterone levels. About 1-2% of total testosterone is free and a further 30-50% is bound with low affinity to albumin; only these two components are bioavailable to the target tissues. In general, assuming the normal reference range for serum total testosterone in adult men is 300-1000 ng/dl (10-35 nmol/l), levels of < 250 ng/dl (8.7 nmol/l) suggest the patient is likely to be hypogonadal, whereas levels of > 350 ng/dl (12.7 nmol/l) suggest the symptoms may not be due to androgen deficiency. Values between 250 to 350 ng/dl warrant a repeat morning serum testosterone determination with assessment of free or bioavailable testosterone. In men with symptoms suggestive of androgen deficiency and borderline serum testosterone levels, where there are no contraindications to androgen therapy, a short therapeutic trial of testosterone may be justified. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:862 / 867
页数:6
相关论文
共 50 条
  • [41] Secondary exposure to testosterone from patients receiving replacement therapy with transdermal testosterone gels
    Miller, Michael G.
    Rogol, Alan D.
    ZumBrunnen, Troy L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 267 - 269
  • [42] Testosterone Replacement Therapy for Sexual Symptoms
    Rastrelli, Giulia
    Guaraldi, Federica
    Reismann, Yacov
    Sforza, Alessandra
    Isidori, Andrea M.
    Maggi, Mario
    Corona, Giovanni
    SEXUAL MEDICINE REVIEWS, 2019, 7 (03) : 464 - 475
  • [43] Testosterone Replacement Therapy in Hypogonadal Men
    Wang, Christina
    Swerdloff, Ronald S.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (01) : 77 - 98
  • [44] Testosterone Replacement Therapy and Prostate Health
    Polackwich, A. Scott
    Ostrowski, Kevin A.
    Hedges, Jason C.
    CURRENT UROLOGY REPORTS, 2012, 13 (06) : 441 - 446
  • [45] Testosterone replacement therapy and the knowledge gap
    Yi, Yooni A.
    Dupree, James M.
    NATURE REVIEWS UROLOGY, 2017, 14 (06) : 332 - U24
  • [46] Selective Use of Testosterone Replacement Therapy
    Loughlin, Kevin R.
    Klap, Julia
    JOURNAL OF UROLOGY, 2016, 196 (05) : 1340 - 1341
  • [47] Testosterone Replacement Therapy in the Treatment of Depression
    Anderson, Danyon J.
    Vazirnia, Parsia
    Loehr, Catherine
    Sternfels, Whitney
    Hasoon, Jamal
    Viswanath, Omar
    Kaye, Alan D.
    Urits, Ivan
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (04):
  • [48] Testosterone replacement therapy for older men
    Borst, Stephen E.
    Mulligan, Thomas
    CLINICAL INTERVENTIONS IN AGING, 2007, 2 (04): : 561 - 566
  • [49] Testosterone replacement therapy in male hypogonadism
    M. M. Byrne
    E. Nieschlag
    Journal of Endocrinological Investigation, 2003, 26 : 481 - 489
  • [50] Andrologische TestosteronersatztherapieAndrological testosterone replacement therapy
    U. Paasch
    H.-J. Glander
    J.-U. Stolzenburg
    Der Urologe, 2009, 48 : 79 - 87